PHAR Pharming Group N.V.

NEUTRAL Impact: 3/10 6-K
Horizon days Filed May 28, 2026 Processed 12d 12h ago SEC 0001828316-26-000029
Notable filing: 6-K
Latest settled — T+5d
PHAR ▼ -10.40% at T+5d
NEUTRAL call ✗ call lost -10.40% · α vs SPY -10.35% · entry $13.66 → $12.24
Next anchor: T+20d in 16d
Currently $12.59 · -7.83% from $13.66 entry
Entry anchored
May 28, 10:38 AM ET
via Databento tick
T+1d
-4.90%
call -4.90% · α -5.14%
$12.99
settled 12d ago
T+5d
-10.40%
call -10.40% · α -10.35%
$12.24
settled 6d ago
T+20d
call — · α —
in 16d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Pharming Group N.V. filed a 6-K reporting the results of its 2026 Annual General Meeting of Shareholders, where shareholders approved all proposals including the appointment of KPMG Accountants N.V. as the new external auditor for 2026-2028, replacing Deloitte. The filing also notes the renewal of authorizations for the Board to issue and repurchase shares. No financial results or material operational updates were disclosed.

Actionable Insight

This is a routine governance filing with no immediate financial impact. Monitor the next quarterly report for any changes in audit findings or financial reporting quality under KPMG. The renewed share issuance and buyback authorizations are standard and do not signal imminent capital actions.

Key Facts

  • Shareholders approved all AGM proposals on May 28, 2026.
  • KPMG Accountants N.V. appointed as external auditor for fiscal years 2026-2028, replacing Deloitte.
  • Deloitte's reports for 2024 and 2025 contained no adverse opinion or disclaimer of opinion.
  • No disagreements or reportable events occurred between the company and Deloitte during the relevant periods, except for previously disclosed material weaknesses in internal control over financial reporting.
  • Authorizations for the Board to issue shares and repurchase shares were renewed.
  • Remuneration policy for Non-Executive Directors' fees was amended.

Financial Impact

No financial figures disclosed in the filing.

Risk Factors

  • Auditor change may lead to adjustments in financial reporting processes or internal controls.
  • Previously disclosed material weaknesses in internal control over financial reporting remain unresolved.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (14 analysts)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001828316-26-000029
Document: 0001828316-26-000029-index-headers.html0001828316-26-000029
Document: 0001828316-26-000029-index.html0001828316-26-000029
Document: 0001828316-26-000029.txt0001828316-26-000029
5 reports for PHAR
Performance horizon
67% Hit rate 2 of 3 directional calls best @ T+20▲ +3.74%Mar 27, 2026
Filters
Rows
Reports for PHAR — sortable, filterable
Type Now
Jun 4, 2026
5d ago
6-K
BULLISH ★ 7/10
$12.47 $12.54▲ +0.57%▲ +3.17%$12.59 (+0.96%)
May 28, 2026
12d ago
6-K
NEUTRAL ★ 3/10
$13.66 $12.99▼ −4.90%▼ −5.14%$12.59 (−7.83%)
May 22, 2026
18d ago
6-K
BULLISH ★ 7/10
$13.62 $13.41▼ −1.54%▼ −1.55%$12.59 (−7.56%)
Apr 16, 2026
7w ago
6-K
NEUTRAL ★ 3/10
$17.33 $17.34▲ +0.06%▼ −1.16%$12.59 (−27.35%)
Mar 27, 2026
10w ago
6-K
BULLISH ★ 8/10
$16.31 $16.01▼ −1.84%▼ −1.48%$12.59 (−22.81%)
Showing 5 of 5

US Market Status

Market Closed — Opens Thu (10h 10m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access